[go: up one dir, main page]

PL3976189T3 - Nowe związki i ich kompozycje farmaceutyczne do leczenia chorób - Google Patents

Nowe związki i ich kompozycje farmaceutyczne do leczenia chorób

Info

Publication number
PL3976189T3
PL3976189T3 PL20728465.4T PL20728465T PL3976189T3 PL 3976189 T3 PL3976189 T3 PL 3976189T3 PL 20728465 T PL20728465 T PL 20728465T PL 3976189 T3 PL3976189 T3 PL 3976189T3
Authority
PL
Poland
Prior art keywords
diseases
treatment
pharmaceutical compositions
novel compounds
novel
Prior art date
Application number
PL20728465.4T
Other languages
English (en)
Inventor
Luke Jonathan ALVEY
Denis BUCHER
Nicolas Desroy
Hélène Marie JARY
Christophe Peixoto
Taoues TEMAL-LAÏB
Amynata TIRERA
Florence Marie-Emilie Bonnaterre
Béranger DUTHION
Original Assignee
Galapagos N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos N.V. filed Critical Galapagos N.V.
Publication of PL3976189T3 publication Critical patent/PL3976189T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL20728465.4T 2019-05-29 2020-05-25 Nowe związki i ich kompozycje farmaceutyczne do leczenia chorób PL3976189T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1907616.5A GB201907616D0 (en) 2019-05-29 2019-05-29 Novel compounds and pharmaceutical compositons thereof for the treatment of diseases
PCT/EP2020/064368 WO2020239658A1 (en) 2019-05-29 2020-05-25 Novel compounds and pharmaceutical compositions thereof for the treatment of diseases

Publications (1)

Publication Number Publication Date
PL3976189T3 true PL3976189T3 (pl) 2024-09-09

Family

ID=67385363

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20728465.4T PL3976189T3 (pl) 2019-05-29 2020-05-25 Nowe związki i ich kompozycje farmaceutyczne do leczenia chorób

Country Status (26)

Country Link
US (1) US12391679B2 (pl)
EP (1) EP3976189B1 (pl)
JP (1) JP7550174B2 (pl)
KR (1) KR20220015450A (pl)
CN (1) CN113924146B (pl)
AR (1) AR119028A1 (pl)
AU (1) AU2020281650B2 (pl)
BR (1) BR112021023900A2 (pl)
CA (1) CA3141683A1 (pl)
CL (1) CL2021003133A1 (pl)
CO (1) CO2021017656A2 (pl)
CR (1) CR20210586A (pl)
DO (1) DOP2021000227A (pl)
EA (1) EA202193281A1 (pl)
ES (1) ES2985528T3 (pl)
GB (1) GB201907616D0 (pl)
IL (1) IL288375B1 (pl)
MA (1) MA56019A (pl)
MX (1) MX2021013803A (pl)
PE (1) PE20220503A1 (pl)
PH (1) PH12021552691A1 (pl)
PL (1) PL3976189T3 (pl)
SG (1) SG11202112652RA (pl)
TW (1) TW202110839A (pl)
WO (1) WO2020239658A1 (pl)
ZA (1) ZA202110597B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018053373A1 (en) 2016-09-16 2018-03-22 The General Hospital Corporation Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis
WO2020182384A1 (en) 2019-03-11 2020-09-17 Inflarx Gmbh Fused piperidinyl bicyclic and related compounds as modulators of c5a receptor
GB201907558D0 (en) * 2019-05-29 2019-07-10 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
AU2021320860A1 (en) * 2020-08-05 2023-02-23 The General Hospital Corporation Salt inducible kinase inhibitors
USD982434S1 (en) * 2021-08-31 2023-04-04 Level Up Dice LLC Dice storage container
CN118119619A (zh) * 2021-10-18 2024-05-31 上海美悦生物科技发展有限公司 Sik抑制剂及其组合物、制备方法和用途
AR128279A1 (es) * 2022-01-19 2024-04-10 Hoffmann La Roche Nuevos derivados de bencimidazol piridina
CN115304605B (zh) * 2022-01-21 2023-10-03 陕西国际商贸学院 具有抗肿瘤活性的氧杂环丁烷衍生物及其制备方法和应用
EP4547663A1 (en) * 2022-07-01 2025-05-07 F. Hoffmann-La Roche AG Imidazo[4,5-c]pyridine derivatives as sik modulators for the treatment of rheumatoid arthritis
US20240124450A1 (en) * 2022-09-21 2024-04-18 Pfizer Inc. Novel SIK Inhibitors
EP4619397A1 (en) * 2022-11-17 2025-09-24 Insilico Medicine IP Limited Salt-inducible kinases (sik) inhibitors and methods of uses thereof
WO2024242169A1 (ja) * 2023-05-24 2024-11-28 田辺三菱製薬株式会社 塩誘導性キナーゼ阻害化合物及びそれを含む医薬組成物
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用
TW202517630A (zh) * 2023-07-19 2025-05-01 瑞士商赫孚孟拉羅股份公司 新穎苯并咪唑吡啶衍生物
WO2025068090A1 (en) * 2023-09-26 2025-04-03 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of diseases
WO2025232877A1 (en) * 2024-05-10 2025-11-13 Insilico Medicine Ip Limited Salt-inducible kinases (sik) inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009014620A1 (en) * 2007-07-20 2009-01-29 Merck & Co., Inc. Pyrazolo[1,5-a]pyrimidine derivatives
WO2012068406A2 (en) * 2010-11-18 2012-05-24 Ligand Pharmaceuticals Incorporated Use of hematopoietic growth factor mimetics
US9676124B2 (en) * 2010-12-01 2017-06-13 Plasan Carbon Composites, Inc. Method and system for forming composite articles
US9512126B2 (en) 2012-03-14 2016-12-06 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
US9260426B2 (en) * 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
JP2018526452A (ja) * 2015-09-03 2018-09-13 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ Dyrk1aの小分子抑制剤およびその使用
CN106496222A (zh) * 2016-09-07 2017-03-15 华东师范大学 一种咪唑并[1,2‑a]吡啶化合物及其制备方法和应用
BR112020010364A2 (pt) 2017-12-02 2021-01-26 Galapagos N.V. compostos e composições farmacêuticas dos mesmos para o tratamento de doenças
CN108358894B (zh) * 2018-04-26 2021-05-07 四川大学 一种抑制组蛋白乙酰转移酶的化合物及其制备方法与应用
CA3103304A1 (en) * 2018-06-15 2019-12-19 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
CN118684661A (zh) 2023-03-21 2024-09-24 上海美悦生物科技发展有限公司 杂芳基类化合物及其药物组合物、制备方法和用途

Also Published As

Publication number Publication date
DOP2021000227A (es) 2022-05-15
PH12021552691A1 (en) 2022-03-14
BR112021023900A2 (pt) 2022-01-18
CO2021017656A2 (es) 2022-01-17
EA202193281A1 (ru) 2022-03-01
AR119028A1 (es) 2021-11-17
MX2021013803A (es) 2021-12-14
TW202110839A (zh) 2021-03-16
ZA202110597B (en) 2024-10-30
US12391679B2 (en) 2025-08-19
WO2020239658A1 (en) 2020-12-03
ES2985528T3 (es) 2024-11-06
CN113924146A (zh) 2022-01-11
EP3976189C0 (en) 2024-07-03
KR20220015450A (ko) 2022-02-08
CR20210586A (es) 2022-01-24
GB201907616D0 (en) 2019-07-10
EP3976189A1 (en) 2022-04-06
CN113924146B (zh) 2024-12-10
CL2021003133A1 (es) 2022-07-22
MA56019A (fr) 2022-04-06
JP2022534578A (ja) 2022-08-02
IL288375B1 (en) 2025-09-01
JP7550174B2 (ja) 2024-09-12
IL288375A (en) 2022-01-01
EP3976189B1 (en) 2024-07-03
CA3141683A1 (en) 2020-12-03
PE20220503A1 (es) 2022-04-07
AU2020281650A1 (en) 2022-02-03
AU2020281650B2 (en) 2025-08-28
US20220340548A1 (en) 2022-10-27
SG11202112652RA (en) 2021-12-30

Similar Documents

Publication Publication Date Title
ZA202110597B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
ZA202004025B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
IL279397A (en) New compounds and their pharmaceutical preparations for the treatment of diseases
GB201907558D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
IL287796A (en) Preparations and methods for the treatment of diseases mediated by ATPase
IL286677A (en) New compounds and their pharmaceutical preparations for the treatment of inflammatory disorders
GB202010464D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
IL286688A (en) New compounds and their pharmaceutical preparations for the treatment of inflammatory disorders
EP3877383A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY DISEASES
GB201911868D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
IL286685A (en) New compounds and their pharmaceutical preparations for the treatment of inflammatory disorders
IL285751A (en) New compounds and their pharmaceutical preparations for the treatment of diseases
IL287392A (en) New compounds and their pharmaceutical preparations for the treatment of kidney diseases
GB201907547D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of hepatitis B
GB201817343D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
GB201817344D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
GB201809836D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
HK40050861A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
PT3586832T (pt) Composição farmacêutica para o tratamento da obstipação
HK40037090A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
GB201720101D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
SG11202112590WA (en) Pharmaceutical compositions for the treatment of hbv
GB201905536D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of metabolic disorders
HK40061034A (en) Compounds and compositions for the treatment of respiratory diseases
HK40072483A (en) Pharmaceutical compositions for the treatment of hbv